| abstract |
The present invention relates to a drug delivery system for controlled release oral administration of a novel angina drug, more particularly, which can be used in vivo using polysaccharides, fatty acid esters and optionally alkalizing agents as well as nicotine from the post-dose preparations. It relates to a sustained release formulation comprising nicolandil exhibiting a release pattern that can be released continuously over 12 to 24 hours. |